Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biofrontera Inc (NQ: BFRI )

3.750 +0.404 (+12.06%)
Streaming Delayed Price Updated: 3:54 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biofrontera Inc

< Previous 1 2 Next >
BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Announces $4.5M Registered Direct
Via Investor Brand Network
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10
Via ACCESSWIRE
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
Via ACCESSWIRE
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)
Via ACCESSWIRE
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
Via ACCESSWIRE
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
Via ACCESSWIRE
Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
Via ACCESSWIRE
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
Via ACCESSWIRE
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)
Via ACCESSWIRE
Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023
Via ACCESSWIRE
Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%
Via ACCESSWIRE
Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects
Via ACCESSWIRE
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors
Via ACCESSWIRE
Biofrontera Inc. Announces 1-for-20 Reverse Stock Split
Via ACCESSWIRE
Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.
Via ACCESSWIRE
Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT
Via ACCESSWIRE
Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer
Via ACCESSWIRE
Biofrontera Inc. Announces Resignation of CEO
Via ACCESSWIRE
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting
Via ACCESSWIRE
Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million
Via ACCESSWIRE
Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention
Via ACCESSWIRE
Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023
Via ACCESSWIRE
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
Via ACCESSWIRE
Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce
Via ACCESSWIRE
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
Via ACCESSWIRE
Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
Via ACCESSWIRE
Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.